Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 11 | 2025 | 227 | 1.930 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 112 | 1.590 |
Why?
|
| Oncologists | 3 | 2021 | 38 | 1.460 |
Why?
|
| Ovarian Neoplasms | 6 | 2022 | 797 | 1.280 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1448 | 0.840 |
Why?
|
| Abortion, Legal | 1 | 2023 | 30 | 0.800 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 93 | 0.790 |
Why?
|
| Cancer Survivors | 2 | 2022 | 88 | 0.700 |
Why?
|
| Drug Costs | 1 | 2021 | 66 | 0.650 |
Why?
|
| Abortion, Induced | 1 | 2023 | 162 | 0.650 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 492 | 0.560 |
Why?
|
| Telemedicine | 1 | 2021 | 225 | 0.540 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2025 | 59 | 0.500 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 1173 | 0.430 |
Why?
|
| Pandemics | 5 | 2022 | 873 | 0.400 |
Why?
|
| Female | 28 | 2025 | 48702 | 0.370 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 1847 | 0.350 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 29 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2544 | 0.340 |
Why?
|
| Humans | 32 | 2025 | 93515 | 0.300 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 277 | 0.300 |
Why?
|
| Quality of Life | 3 | 2022 | 1780 | 0.300 |
Why?
|
| Endometrial Hyperplasia | 2 | 2022 | 11 | 0.290 |
Why?
|
| Palliative Care | 2 | 2021 | 269 | 0.280 |
Why?
|
| Aged | 16 | 2025 | 20434 | 0.260 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 7061 | 0.250 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 159 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 2017 | 0.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 1053 | 0.190 |
Why?
|
| Mental Health | 2 | 2021 | 188 | 0.190 |
Why?
|
| Electronics | 1 | 2022 | 19 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 624 | 0.180 |
Why?
|
| Middle Aged | 15 | 2025 | 27573 | 0.180 |
Why?
|
| Frailty | 1 | 2023 | 94 | 0.170 |
Why?
|
| Morbidity | 1 | 2022 | 162 | 0.170 |
Why?
|
| Decision Trees | 1 | 2021 | 64 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.170 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 64 | 0.170 |
Why?
|
| Markov Chains | 1 | 2021 | 135 | 0.170 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 97 | 0.170 |
Why?
|
| Quinolines | 1 | 2021 | 85 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 59 | 0.170 |
Why?
|
| Hysterectomy | 3 | 2019 | 167 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2021 | 75 | 0.160 |
Why?
|
| Chicago | 3 | 2020 | 1464 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 156 | 0.160 |
Why?
|
| Depression | 2 | 2021 | 544 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 283 | 0.160 |
Why?
|
| Carboplatin | 1 | 2021 | 322 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 184 | 0.150 |
Why?
|
| Paclitaxel | 1 | 2021 | 479 | 0.150 |
Why?
|
| Adult | 12 | 2025 | 27918 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2020 | 375 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1161 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 1001 | 0.140 |
Why?
|
| Health Resources | 1 | 2018 | 80 | 0.140 |
Why?
|
| Communication | 1 | 2021 | 434 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2021 | 342 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 300 | 0.140 |
Why?
|
| Health Equity | 1 | 2020 | 101 | 0.130 |
Why?
|
| Self Care | 1 | 2018 | 167 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 446 | 0.130 |
Why?
|
| Neoplasms | 2 | 2023 | 3169 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 576 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 91 | 0.120 |
Why?
|
| Pregnancy | 1 | 2023 | 3147 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10164 | 0.120 |
Why?
|
| Corneal Injuries | 1 | 2015 | 8 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 314 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 168 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 512 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 486 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 179 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 394 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1061 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2015 | 328 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1018 | 0.090 |
Why?
|
| Prostatectomy | 1 | 2015 | 478 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2012 | 150 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 3911 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2012 | 384 | 0.080 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 92 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 326 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 318 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 985 | 0.070 |
Why?
|
| Anxiety | 2 | 2021 | 337 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 304 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 636 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 6930 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2562 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 1170 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2303 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1660 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1077 | 0.060 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 129 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 9606 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 889 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1931 | 0.050 |
Why?
|
| Incidence | 2 | 2021 | 1701 | 0.050 |
Why?
|
| United States | 3 | 2021 | 7622 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5899 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2007 | 1524 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 3054 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1906 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 188 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2021 | 17 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 9099 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 240 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 170 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 204 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 990 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 876 | 0.040 |
Why?
|
| Social Class | 1 | 2020 | 141 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 137 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 22 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 304 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 233 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 234 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 193 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 557 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 66 | 0.030 |
Why?
|
| Endometrium | 1 | 2015 | 51 | 0.030 |
Why?
|
| Sexuality | 1 | 2015 | 40 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 213 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 196 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 402 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 328 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 413 | 0.020 |
Why?
|
| Robotics | 1 | 2015 | 269 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 229 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2012 | 126 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 368 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1243 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 657 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1546 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2465 | 0.020 |
Why?
|
| Child | 1 | 2021 | 7355 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1741 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2015 | 782 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1775 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 5410 | 0.010 |
Why?
|
| Male | 1 | 2015 | 44557 | 0.010 |
Why?
|